{"id":"NCT00418717","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA","officialTitle":"An Open-label, Multicenter, Dose-regimen Study Evaluating the Efficacy and Safety of Etanercept 50 mg Once-weekly Dose in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2007-01-05","resultsPosted":"2010-05-04","lastUpdate":"2012-03-02"},"enrollment":42,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"etanercept","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to evaluate the safety and efficacy of a once-weekly dose of etanercept for rheumatoid arthritis. Currently, patients in Japan can only use 25 mg etanercept two times a week. If a once-a-week regimen of 50 mg is approved, this would be more convenient for most patients. This once-weekly regimen is used in countries outside of Japan.","primaryOutcome":{"measure":"Disease Activity Score Using 28-joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4ESR) by Treatment Period.","timeFrame":"weeks 4 and 12","effectByArm":[{"arm":"Etanercept (ETN)","deltaMin":3.26,"sd":0.66}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":12,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Infections and Infestations","Dizziness","Stomatitis","Headache","Pharyngolaryngeal pain"]}}